엘앤케이바이오 Stock: price and insider trades · South Korea

엘앤케이바이오 is a Health Care company. Its directors and officers file their transactions with DART (FSS). From 5 November 2025 to 5 November 2026, the disclosure feed for 엘앤케이바이오 logged 7 filings by 2 insiders.

No insider sold shares on the market over the period. Instead, the filings list 6 purchases, made by 1 insider. The totals do not cover 6 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 major shareholder and 1 chief executive among the declarants.

The clock since the last published purchase (3 August 2026) now reads 99 days. The median gap between a trade and its publication by DART (FSS) is 1 day. This delay matters because a trade only becomes useful information once it is public.

For context, the typical company on the same exchange (median of 2,656 companies) published 7 filings over the same period, against 7 filings here. Over the whole record (from 2021), the tally stands at 7 purchases and 2 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.